Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
Gian Maria Busetto(Sapienza University of Rome), Luigi Cormio(University of Foggia), Carlo Bettocchi(University of Foggia), Ugo Giovanni Falagario(Ospedali Riuniti di Foggia), Beppe Calò(Ospedale L. Bonomo), Matteo Ferro(European Institute of Oncology), Ettore De Berardinis(Policlinico Umberto I), Marco Chirico(University of Foggia), Vito Mancini(University of Foggia), Marco Finati(University of Foggia), Angelo Porreca(Istituto Oncologico Veneto), Francesco Cinelli(University of Foggia), Felice Crocetto(University of Naples Federico II), Nicola d’Altilia(Ospedali Riuniti di Foggia), L. Di Gianfrancesco(Università Cattolica del Sacro Cuore), Giuseppe Carrieri(University of Foggia), Francesco Del Giudice(Sapienza University of Rome), Francesca Sanguedolce(University of Foggia)
Cited by 7
Related Papers
European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2021 Update on Male Infertility
|European Urology|2021|612
Male Oxidative Stress Infertility (MOSI): Proposed Terminology and Clinical Practice Guidelines for Management of Idiopathic Male Infertility
|The World Journal of Men s Health|2019|468
Sperm recovery and ICSI outcomes in men with non-obstructive azoospermia: a systematic review and meta-analysis
|Human Reproduction Update|2019|305
Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non–muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection
|European Urology|2019|212
Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets
|International Journal of Molecular Sciences|2022|190